Stevia (STEV) News Today

Stevia Corp. (STEV) shares are reacting to a mix of fresh health‐science research on stevia and a wave of industry recalls affecting consumer confidence in natural sweeteners.

• Positive Sentiment: New clinical data suggest stevia extract may help fight pancreatic cancer, boosting long-term demand for stevia-based products. Can this popular sugar substitute fight pancreatic cancer? Here's what new study says
• Positive Sentiment: Japanese researchers report a breakthrough using fermented stevia extract as a potential cancer therapy, underlining stevia’s expanding health-science credentials. Fermented Stevia extract as cure for pancreatic cancer possible, Japanese scientists make a breakthrough using sugar substitute
• Neutral Sentiment: Consumer guidance piece on sugar-free options for diabetics highlights both benefits and cautionary risks, with no direct impact on STEV’s core business. Is sugar-free really safe for diabetics? Benefits, risks, and smart choices diabetics should know
• Negative Sentiment: FDA has upgraded the NuNaturals sweetener recall—including stevia and monk fruit products—to a Class II health risk, raising concerns over product safety in the category. Food and Drug Administration raises NuNaturals sugar-free sweetener recall to Class II risk
• Negative Sentiment: Broader FDA alert over label mix-ups in popular sweeteners has spurred multiple recalls, denting consumer confidence in stevia brands. Popular sweeteners recalled as FDA updates health risk